ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1256

Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over

Serdal Ugurlu1, Okan Aydin 2 and Huri Ozdogan 2, 1Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey, 2Istanul University-Cerrahpasa, istanbul, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Familial Mediterranean fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Familial Mediterranean fever (FMF) is a disease with an onset before 20 years of age in 90% of the patients.  However late onset FMF defined as age of onset over 40 years is being recognized more frequently. To better define patients with FMF who had their first attack before age 40 and compare them with early onset patient group in Turkish population

Methods: The files of 2180 FMF patients followed in a single center between 2008-2017 who have fulfilled Tel-Hashomer criteria, were reviewed regarding the age of onset 40 years and over (index patients, Group 1).  For control purposes files before and after the index patients were browsed and first patients with an onset before age 20 years (Group 2) were included. The demographic, clinical and genetic characteristics are compared between these 2 subgroups.

Results: Patients with an onset after 40 years consisted 2.7% of our FMF population. 50 of the 59 patients with an onset 40 years or over were re-evaluated and compared with early onset group consisting of 100 patients (Table 1).  The delay in diagnosis, and disease duration were significantly longer and number of patients with M694V homozygosity and M694V allele frequency were significantly more frequent among group 2. In general, phenotypes of both onset groups were similar, the only significant differences being the frequency of fever and myositis which were less common among group 1. Also, response to colchicine was more pronounced in group 1. One other interesting observation was the low incidence of amyloidosis in a group with such a significant delay in diagnosis and thus treatment.

Conclusion: FMF should be included among the differential diagnosis of patients over 40 years of age with recurrent autoinflammatory manifestations. Less than 3% of FMF patients experience their first attacks after 40 years of age. The frequency of M694V is significantly less in the late onset group, pointing out a milder disease.

Table 1. Demographic, clinical and genetic features of the study groups


Disclosure: S. Ugurlu, None; O. Aydin, None; H. Ozdogan, None.

To cite this abstract in AMA style:

Ugurlu S, Aydin O, Ozdogan H. Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/comparison-of-fmf-patients-with-age-of-onset-before-20-versus-40-years-and-over/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-fmf-patients-with-age-of-onset-before-20-versus-40-years-and-over/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology